Author’s response to reviews

Title: Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B

Authors:
Yue Ying (10300300055@fudan.edu.cn)
Yue-Kai Hu (huyuekai@fudan.edu.cn)
Jia-Lin Jin (jinjialin@fudan.edu.cn)
Ji-Ming Zhang (jmzhang@fudan.edu.cn)
Wen-Hong Zhang (zhangwenhong@fudan.edu.cn)
Yu-Xian Huang (yxhuang@fudan.edu.cn)

Version: 2 Date: 03 Jan 2018

Dear editor,

We thank you very much for giving us an opportunity to be potentially acceptable for publication in BMC Gastroenterology. We appreciate you and reviewers very much for your positive and constructive comments and suggestions on our manuscript entitled “Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B” (BMGE-D-17-00374R1). We have studied your comments carefully and carried out some essential revisions.

For reviewer 1’s comments:

1. We thank you for your suggestions on describing the disease history more exactly. We changed the sentence as “the patient denied a past history of significant comorbidities, including diabetes and chronic kidney disease”, which showed in page 5, line 15-16.
2. Thank you for your help to improve our manuscript about the patient’s drug history. We are happy to know it becoming reasonable now.

3. Thank you for the suggestions. We revised the sentence as “Total bilirubin and indirect bilirubin levels were normal”, which presented in page 4, line 22.

4. We did as suggest, changed the words as “rule out liver cancer” in page 5, line 1.

5. Thanks for your approval to our revision about therapy to acidosis. We are happy to know it becoming reasonable now.

6. Thanks for your suggestions about offering more details to establish the diagnosis of rhabdomyolysis. We are happy to know it reasonable now.

7. We agree that “warm skin” is more suitable than “higher skin temperature”. You can see the change in page 5, line 14.

8. It’s so kind of you to point out that we should make it clear about the reason of changing strategy of antiviral treatment. We are happy to know it reasonable now.

9. Thank you for the approval to our revision.

10. We agree that it is important to have this case report to demonstrate the real-world findings, although there were no such reports in the clinical trials. We hope that it can attract attention to the adverse drug reaction caused by combination of telbivudine and tenofovir.

For reviewer 2’s comments, thank you for your encouragement. We will do our best to improve further.

We enclosed our revised version without highlighting, which all changes are only pointed out in this letter, for your kind consideration. We hope that the revised manuscript is now suitable for publication.

Looking forward to hearing from you. Thank you and best regards.
Best wishes,

Ying Yue

Corresponding author:

Name: Huang Yu-xian

Address: Huashan Hospital Fudan University, Department of Infectious disease, 12 Middle Wulumuqi Rd, Building 5, Room 504, Shanghai, CN 200040

Phone: +8602152887954

E-mail address: yxhuang@fudan.edu.cn